Voruciclib also downregulates Mcl-1, a common player in venetoclax resistance, though the downregulation of c-Myc proved to be more important in the enhancement of venetoclax activity than Mcl-1 downregulation.109 Voruciclib is currently being tested in a phase I, open-label, 3 + 3 dose escalation clinical trial for the treatment of AML and B cell malignancies post treatment with standard therapy (NCT03547115). Here, MCL1 is linked to acute myeloid leukemia.